The focus of Dr. Dhall’s clinical research is to design and conduct clinical trials utilizing treatment strategies that either avoid or at least minimize the dose and volumes of irradiation in infants and young children with malignant brain tumors. His clinical trials also innovatively focus on children and young adults with CNS germ cell tumors
He has successfully chaired many local and multi-institutional clinical trials and has been involved in many leadership roles on various national committees, including the chairmanship of the Young Investigator’s Committee in Children’s Oncology Group (COG). He also serves as the Vice-Chair of the Institutional Review Board at CHLA and has mentored many students, residents, fellows, and junior faculty over the last 10 years who have now taken leadership roles at many prestigious institutions across the country.
Caring for children and young adults with primary brain and spinal cord tumors.
Grant Medical College, Mumbai, India
Sir J.J. Hospital and Grant Medical College, Mumbai, India
B.Y.L. Nair Hospital and T.N. Medical College, Mumbai, India; Saint Vincent’s Hospital and Medical Center, New York, NY
New York University Medical Center/NYU School of Medicine; Children’s Hospital Los Angeles/University of Southern California
American Board of Pediatrics, October 2000; Pediatric Hematology-Oncology, November 2006
American Society of Pediatric Hematology-Oncology
Fellow of American Academy of Pediatrics
Society for Neuro-Oncology
American Society of Clinical Oncology
International Society of Pediatric Oncology
Society for Pediatric Research
Excellence in Teaching Award
Pasadena Magazine Top Doctors Award
Saban Clinical Research Academic Career Development Award
Walter Laug Distinguished Teacher Award for Outstanding Teaching, Guidance and Inspiration
“Dare to Dream” Award in Recognition of Excellence
Commendation from the County of Los Angeles in recognition of dedicated service to the affairs of the community and for the civic pride demonstrated by numerous contributions for the benefit of all the citizens of Los Angeles County.
Margol AS, Robison NJ, Gnanachandran J, Hung LT, Kennedy RJ, Vali M, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, and Asgharzadeh S. Tumor-associated macrophages in SHH subgroup of Medulloblastomas. Clin Cancer Res. 2015 Mar 15;21(6):1457-65. [Epub 2014 Oct 24].
Evans AC, Nelson MB, Dhall G. Pregnancy in a patient with malignant brain tumor taking Temozolomide: Case report and review of the literature. J Pediatric Oncol Nurs. 2015 Sept;32(5):326-8. [Epub 2015 Jan 9].
Zaky W, Dhall G, Khatua S, Brown RJ, Ginn KF, Gardner SL, Yildiz VO, Yankelevich M, Finlay JL. Choroid Plexus Carcinomas in Children: The Head Start Experience. Pediatr Blood Cancer. 2015 May;62(5):784-9. [Epub 2015 Feb 8].
Pruitt R, DaSilva NS, Cappellano A, Belessiotis C, Diez B, Gardner S, Allen J, Weinblatt M, Gottardo N, Dhall G, Finlay JL. Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiation: Findings from the Third International Central Nervous System (CNS) germ cell tumor (GCT) study. Pediatr Blood Cancer, 2015 Jun 5 [Epub ahead of print].
Bluml S, Margol A, Sposto R, Kennedy RJ, Robison NJ, Vali M, Hung LT, Muthugounder S, Finlay JL, Erdreich-Epstein A, Gilles FH, Judkins AR, Krieger MD, Dhall G, Nelson MD, Asgharzadeh S. Molecular subgroups of medulloblastoma identification using non-invasive magnetic resonance spectroscopy. Neuro Oncol 2015 Aug 8. [Epub ahead of print].
Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, and Dhall G. Allergic reactions and anti-asparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A Children’s Oncology Group Report. Accepted for publication in Cancer.
Girish Dhall, MD, is dedicated to improving the survival rate of young children with brain tumors without using radiation therapy or minimizing the dose and volume of radiation therapy, which can cause severe and irreversible damage to intellectual functioning. He is investigating innovative approaches for children who fail to respond to standard therapy; a mix of chemotherapy, radiation therapy, biologic therapy, and autologous hematopoietic stem cell transplantation.
Dhall’s clinical research goal is to discover novel, research-based diagnostic and treatment options for brain and spinal cord tumors, which can be offered to patients of the Neuro-Oncology Program at Children’s Hospital Los Angeles. He serves as CHLA’s institutional principal investigator for a number of important clinical trial research consortia including:
- Pediatric Brain Tumor Consortium - the study of correlative tumor biology and new therapies for primary CNS tumors of childhood with the objective to rapidly conduct novel phase I and phase II clinical evaluations of new therapeutic drugs, new biological therapies, treatment delivery technologies and radiation treatment strategies in children from infancy to 21 years of age with primary central nervous system tumors.
- Neurofibromatosis (NF) Clinical Trials Consortium –clinical trials of novel medications in the treatment and prevention of neurofibromatosis.
- Collaborative Ependymoma Research Network (CERN) – adult and pediatric neuro-oncologists working to find new treatments for ependymoma, a malignant brain tumor often found in young infants and children
- Pacific Pediatric Neuro-Oncology Consortium (PNOC) – innovative clinical trials based on cutting-edge research in children and young adults with malignant brain tumors.
Visit the Dhall Laboratory.